Posting Date: April 22, 2021

Closing Date: May 2, 2021 11:30 a.m. ET

Reference Number: 21-032112

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Laboratory Testing Services

At the National Cancer Institute (NCI), The Laboratory of Pathology (LP) is an integral component of the research and clinical community. Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education. We support the research mission of the NCI by investigating the biology and genetics of cancer and other diseases, developing and applying leading edge technology to diagnostic pathology, providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles.

The National Cancer Institute plans to purchase Laboratory Testing Services for HTG EdgeSeq miRNA WTA ILM (1x96) from HTG Molecular. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on May 2, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The Contractor is the OEM for the EdgeSeq system and as these samples have already been prepared using proprietary EdgeSeq lysis buffer, only the EdgeSeq system can be used. This acquisition has been requested because a prior attempt to use in-house NCI core laboratory services to process these samples did not produce viable data.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request